SCHEMBL26808918

SCHEMBL26808918

Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2ccc(N3CCN(C)CC3)cc2)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD52 P43351 2/20 0.39
▸ BRD4 O60885 3/20 0.38
▸ MAP4K1 Q92918 1/20 0.37
▸ PDE2A O00408 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ ITK Q08881 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ JAK2 O60674 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567356 1.00 RAD52 (0.39) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL24310431 0.92 HTR2C (0.41) RAD52BRD4JAK2HRH4HTR1A
SCHEMBL29566298 0.92 HTR2C (0.41) RAD52BRD4JAK2HRH4HTR1A
SCHEMBL29567239 0.91 RAD52 (0.39) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL24309717 0.91 RAD52 (0.39) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL29567000 0.91 PDE2A (0.40) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL24310422 0.91 PDE2A (0.40) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL26808704 0.91 RAD52 (0.39) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL24310167 0.89 RAD52 (0.37) RAD52BRD4MAP4K1PDE2APDE10A
SCHEMBL29566354 0.89 RAD52 (0.37) RAD52BRD4MAP4K1PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B RAD52 4705/4885BRD4 1716/4885MAP4K1 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback